Related Experiment Videos
Direct thrombin inhibitors
1McMaster University, Hamilton General Hospital, Hamilton, Ont., Canada.
Insights
Direct thrombin inhibitors like hirudin and bivalirudin show promise for acute coronary syndromes (ACS). While hirudin is effective, it increases bleeding risk; bivalirudin may offer similar efficacy with improved safety compared to unfractionated heparin.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Direct thrombin inhibitors present potential advantages in managing acute coronary syndromes (ACS) compared to indirect inhibitors.
- Hirudin and bivalirudin are two direct thrombin inhibitors that have undergone clinical investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of direct thrombin inhibitors, specifically hirudin and bivalirudin, in patients with ACS.
- To compare these agents against unfractionated heparin (UFH).
Main Methods:
- Meta-analysis of clinical trial data from a large patient population (25,000 patients) for hirudin.
- Meta-analysis of a smaller patient cohort for bivalirudin.
Main Results:
- Hirudin demonstrated greater effectiveness than UFH in ACS treatment but was linked to a higher incidence of major bleeding.
- Preliminary findings suggest bivalirudin may be more efficacious and safer than UFH in ACS patients.
Conclusions:
- Direct thrombin inhibitors, particularly bivalirudin, warrant further investigation for ACS management due to potential efficacy and safety benefits.
- Balancing efficacy and bleeding risk is crucial when selecting anticoagulants for ACS.
Abstract:
Direct thrombin inhibitors may offer advantages over indirect thrombin inhibitors in the management of patients with acute coronary syndromes (ACS). Two direct thrombin inhibitors, hirudin and bivalirudin, have been investigated in Phase II and Phase III clinical trials. Based on the results of a meta-analysis of study data from 25,000 patients, hirudin appears to be more effective than unfractionated heparin (UFH) in the treatment of patients with ACS, but it is associated with an increased rate of major bleeding. A meta-analysis of a smaller patient population has suggested that bivalirudin, too, may be more efficacious than UFH and may also be safer.